According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
The cornerstone of the quality ecosystem is the implementation of the Quality Control Orders
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Subscribe To Our Newsletter & Stay Updated
